According to an article published this week in JAMA Oncology, nearly 1 in 5 cancer patients surveyed said the pandemic would make them less likely to enroll in a trial. The top reason given for not enrolling is fear of COVID-19 exposure.
Today the U.S. Senate released its FY 2021 spending bill that includes a $2 billion funding increase for the National Institutes of Health (NIH), including a $282 million funding boost for the National Cancer Institute (NCI). The proposal also includes the Henrietta Lacks Enhancing Cancer Research Act.
Twenty patient groups representing millions of Americans with pre-existing conditions are urging the U.S. Supreme Court to prioritize patient protections, including those for people with pre-existing conditions, when it hears oral arguments Tuesday in the case of California v. Texas (previously Texas v. United States).
The American Cancer Society Cancer Action Network (ACS CAN) today released a report detailing the costs of treating cancer, specifically out-of-pocket costs typical cancer patients face. The report found U.S. cancer patients in 2018 spent $5.6 billion in out-of-pocket costs for cancer treatment
Cancer patients and survivors continue to experience potentially serious coronavirus-related health care delays and high levels of anxiety associated with the ongoing pandemic.
As part of a broader health care package the administration issued an executive order today to preserve health coverage protections for people with pre-existing conditions should the Supreme Court invalidate the Affordable Care Act (ACA).
A statement from Gary M. Reedy, CEO of the American Cancer Society and American Cancer Society Cancer Action Network (ACS CAN) follows on the death of Supreme Court Justice, Ruth Bader Ginsburg from complications from pancreatic cancer
The Trump administration issued an executive order Sunday that would significantly change how Medicare pays for certain prescription drugs. The “Most Favored Nation” policy would tie Medicare drug reimbursement for certain drugs under Part B and D to that of prices paid in select foreign countries.